Drugs / Ex Vivo-activated Autologous Lymph Node Lymphocytes
Ex Vivo-activated Autologous Lymph Node Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02530515 | Dec 2015 → Apr 2018 | Richter transformation, anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, infectious disease +5 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex Vivo-activated Autologous Lymph Node Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530515 ↗ |
| Modality | Cell therapy | “infusion of autologous activated T-cells (ex vivo-activated autologous lymph node lymphocytes)” NCT02530515 ↗ |
| Route | Intravenous | “Given IV” NCT02530515 ↗ |